Visit https://www.peervoice.com/EAJ860 to view the entire programme with slides. After completing “Naveen Pemmaraju, MD - How I Treat BPDCN: A Case-Based Exploration of Best Practices in Selecting and Providing Therapeutic Strategies”, participants will be able to: Recognize guideline-recommended best practices in the diagnostic assessment and therapeutic management of patients presenting with blastic plasmacytoid dendritic cell neoplasm (BPDCN); Implement evidence-based best practice approaches to the diagnosis of BPDCN in patients presenting with symptoms of this condition; and Formulate appropriate management plans for patients with BPDCN, including selecting initial therapy, identifying candidates for stem cell transplant, and providing adverse event monitoring and management plans in patients receiving targeted therapy.

Visit https://www.peervoice.com/DHX860 to view the entire programme with slides. After completing “Alicia K. Morgans, MD, MPH - Clinical Conversations in Castration-Resistant Prostate Cancer: Best Practices in Discussing Testing and Treatment With Patients”, participants will be able to: Implement recommended patient communication approaches when discussing mutational testing in metastatic castration-resistant prostate cancer (mCRPC), including what tests involve, what impact a positive result means for treatment options, and how to empower patients to make informed decisions about their treatment plan

Visit https://www.peervoice.com/MYY860 to view the entire programme with slides. After completing “Vijay Ramaswamy, MD, PhD, FRCPC / Sébastien Perreault, MD, FRCPC / Lucie Lafay-Cousin, MD - Spot, Act, and Treat: Canadian Consensus Updates on Neurofibromatosis Type 1-Associated Plexiform Neurofibromas”, participants will be able to: Identify strategies to streamline referral for patients with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (PN) in the Canadian landscape; Evaluate consensus-based approaches for managing patients with NF1-associated PN across the continuum of care; and Support strategies to ensure effective transition from pediatric to adult care for patients with NF1-associated PN.

Visit https://www.peervoice.com/MBM860 to view the entire programme with slides. After completing “Natasha Leighl, MD, MMSc, FRCPC, FASCO - Targeting Improved Outcomes in ALK-Positive NSCLC: A Canadian Clinician’s Guide to Optimizing Outcomes Across the Spectrum of Disease”, participants will be able to: Discuss the rationale for adjuvant targeted therapy in resectable ALK-positive NSCLC; Evaluate the latest clinical data of targeted therapy in resectable ALK-positive NSCLC; and Identify patient factors to guide therapy selection in resectable NSCLC.

Visit https://www.peervoice.com/RRA860 to view the entire programme with slides. After completing “Neal Shore, MD, FACS - Redefining Expectations in mHSPC: Options and Opportunities Across the Spectrum of Disease”, participants will be able to: Identify persistent gaps in the provision of patient-centred care for metastatic hormone-sensitive prostate cancer (mHSPC); Assess novel evidence related to PSA response and its association with clinical outcomes in patients with mHSPC; Evaluate the efficacy and safety of treatment regimens for mHSPC based on patient and disease characteristics such as age, disease volume, and disease risk; and Identify patient comorbidities, concomitant drug regimens, and preferences that may inform treatment planning in mHSPC.

Visit https://www.peervoice.com/EMZ860 to view the entire programme with slides. After completing “Lorenza Rimassa, MD - Shifting the Paradigm in Biliary Tract Cancers: Contemporary Data and Decision-Making”, participants will be able to: Evaluate current efficacy and safety data related to the use of targeted therapies in the treatment of advanced or metastatic biliary tract cancer (BTC); Apply best practices and guideline recommendations for timely molecular testing of BTC; and Design personalised treatment regimens for individual patients with BTC based on current evidence and guidelines.

Visit https://www.peervoice.com/BEZ860 to view the entire programme with slides. After completing “Alison Birtle, FRCP, FRCR, MD - Case Study Challenge in Advanced Bladder Cancer: Tailoring Treatment to Individual Patients”, participants will be able to: Assess the clinical implications of clinical trial data and real-world evidence evaluating available treatment regimens for the first-line management of advanced bladder cancer; and Formulate individualised management plans for the first-line management of advanced bladder cancer considering factors such as patient age, fitness, goals of therapy and eligibility for cisplatin and carboplatin.

Visit https://www.peervoice.com/DGN860 to view the entire programme with slides. After completing “Adam Brufsky, MD, PhD / Rebecca Dent, MD, FRCP (Canada) - Same Class, Different Agents: Practical Considerations for Managing Toxicities of Interest in Patients on TROP2-Directed Therapies in Breast Cancer”, participants will be able to: Assess the clinical significance of clinical trial data evaluating the safety and efficacy of TROP2-directed antibody-drug conjugate (ADC) therapy in the management of advanced breast cancer; Identify common adverse events associated with the use of TROP2-directed agents in the management of advanced breast cancer; and Implement evidence-based best practices in the monitoring, identification and management of adverse events in patients with advanced breast cancer receiving TROP2-directed therapy.

Visit https://www.peervoice.com/EQW860 to view the entire programme with slides. After completing “Peter Schmid, FRCP, MD, PhD - Use of Neoadjuvant Chemoimmunotherapy Followed by Adjuvant Immunotherapy in Early-Stage TNBC: A Case-Based Discussion”, participants will be able to: Identify high-risk patients with early-stage triple-negative breast cancer (TNBC) who may benefit from neoadjuvant chemoimmunotherapy, followed by adjuvant immunotherapy; Outline evidence-based, patient-centered strategies to optimally integrate neoadjuvant and adjuvant immunotherapy into practice for patients with early-stage TNBC; and Describe how to manage immune-related adverse events associated with neoadjuvant and adjuvant immunotherapy in early-stage TNBC.

Visit https://www.peervoice.com/XNA860 to view the entire programme with slides. After completing “Natasha Leighl, MD, MMSc, FRCPC, FASCO - Raising the Bar With Immunotherapy in Early-Stage NSCLC: Insights to Inform Treatment Decisions”, participants will be able to: Describe the evidence with immunotherapy-based regimens in resectable early-stage non–small-cell lung cancer (NSCLC); Propose strategies to optimize multidisciplinary collaboration in the care of patients with resectable early-stage NSCLC; and Illustrate the optimal use of immunotherapy-based regimens for patients with resectable early-stage NSCLC.

Visit https://www.peervoice.com/QTY860 to view the entire programme with slides. After completing “Shannon Salvador, MD, MSc, FRCSC - Advancing Frontline Endometrial Cancer Care: Translating the Latest Advances in Immunotherapy Plus Chemotherapy Regimens to Practice”, participants will be able to: Evaluate the clinical impact of first-line immunotherapy plus chemotherapy-based regimens in treating primary advanced or recurrent endometrial cancer; Identify patients who are eligible for first-line immunotherapy plus chemotherapy-based regimens for the treatment of primary advanced or recurrent endometrial cancer; and Outline personalized strategies to optimize outcomes for patients with primary advanced or recurrent advanced endometrial cancer on first-line immunotherapy plus chemotherapy combinations.

Visit https://www.peervoice.com/HDT860 to view the entire programme with slides. After completing “Diana N. Ionescu, MD - Standardizing pCR Assessment in Early-Stage Breast Cancer: Evaluating Rationale, Methods, and Common Pitfalls”, participants will be able to: Review how to assess pathologic complete response (pCR) in patients with early-stage breast cancer following neoadjuvant therapy; Evaluate how to overcome common challenges in pCR assessment for patients with early-stage breast cancer following neoadjuvant therapy; and Outline strategies to optimize pCR assessment in early-stage breast cancer.

Visit https://www.peervoice.com/WPM860 to view the entire programme with slides. After completing “Giada Sebastiani, MD, FAASLD - Shedding Light on the Detection and Management of MASLD/MASH: Expert Insights to Improve Outcomes”, participants will be able to: Outline the epidemiology of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) and risk factors in patients with metabolic diseases; Describe recent guidelines for the screening of MASLD/MASH; Identify best practices to facilitate the early detection of MASLD/MASH in patients with metabolic diseases; Discuss the underlying pathophysiology and therapeutic targets in MASLD/MASH; and Formulate management strategies that may improve outcomes in patients with MASLD/MASH and comorbid conditions.

Visit https://www.peervoice.com/HUF860 to view the entire programme with slides. After completing “Chloe E. Atreya, MD, PhD / Marwan Fakih, MD - Focusing on the Patient in Front of Us: Expert Perspectives on Providing Patient-Centered Care for Refractory Metastatic Colorectal Cancer”, participants will be able to: Use patient-, disease-, and therapy-specific considerations to guide treatment decision-making for refractory metastatic colorectal cancer (mCRC) that has progressed through recommended systemic regimens; Evaluate patient preferences related to treatment planning and sequencing for refractory mCRC through the application of best practices for patient education and patient-provider communication; and Design patient counseling and follow-up plans that integrate multidisciplinary team (MDT) members and are aimed at promoting adherence to, and tolerance of, chemotherapy regimens.

Visit https://www.peervoice.com/QZP860 to view the entire programme with slides. After completing “Krista Noonan, BSc, MD, FRCPC / Elizabeth R. Plimack, MD, MS, FASCO - Redefining the Standards of Care in RCC: Expert Insights to Translate Recent Advances to Clinical Practice”, participants will be able to: Discuss the role of immunotherapy in early-stage renal cell carcinoma (RCC); Propose strategies to explain adjuvant treatment to patients, to achieve a shared decision; Evaluate how prior treatments influence the choice of subsequent lines of therapy in advanced RCC; and Formulate evidence-based approaches for identifying and managing adverse events with new therapies for advanced RCC.

Visit https://www.peervoice.com/SAU860 to view the entire programme with slides. After completing “Robert J. Motzer, MD - Advanced Renal Cell Carcinoma: Clinical Advances in Approaches to Combination Therapy”, participants will be able to: Evaluate the available safety and efficacy data from trials examining current and emerging therapies, including combination regimens, in advanced renal cell carcinoma (RCC); Identify and assess adverse events (AEs) associated with combination therapy in patients with advanced RCC; and Apply recommended strategies and incorporate patient preferences in the management of AEs associated with combination therapy in advanced RCC.

Visit https://www.peervoice.com/ZXH860 to view the entire programme with slides. After completing “Dustin A. Deming, MD - Personalizing Treatment Pathways for Refractory Metastatic Colorectal Cancer: Informed Decision-Making When Disease Has Progressed”, participants will be able to: Apply evidence-based and guideline-recommended best practices for molecular testing and identification of disease progression to guide treatment planning and sequencing for refractory metastatic colorectal cancer (mCRC); Evaluate efficacy and safety data for recommended treatments for mCRC that have progressed through prior treatments; and Identify patient-, disease-, and therapy-specific considerations that influence choice of therapy in patients with refractory mCRC.

Visit https://www.peervoice.com/FKD860 to view the entire programme with slides. After completing “Diana N. Ionescu, MD - To Target We Need to Test: Why and How to Identify Folate Receptor Alpha-Positive Ovarian Cancer”, participants will be able to: Use the clinical data for folate receptor alpha (FRɑ)-targeted therapies for ovarian cancer to evaluate the need for establishing FRɑ status; Describe the immunohistochemical characteristics of FRɑ-positive ovarian cancer; and Apply guideline recommendations for FRɑ testing and targeted treatment in patients with ovarian cancer.

Visit https://www.peervoice.com/YCX860 to view the entire programme with slides. After completing “Alon Altman, MD, FRCSC, CCPE - It Takes Two: Integrating Immunotherapy in Combination With Chemotherapy Into Recurrent or Primary Advanced Endometrial Cancer Care”, participants will be able to: Discuss current unmet needs in the frontline management of advanced endometrial cancer and the rationale for immunotherapy-chemotherapy combinations in this setting; Evaluate the clinical data for immunotherapy plus chemotherapy combinations for recurrent or primary advanced endometrial cancer; and Outline how to individualize treatment selection and manage safety concerns with available combination regimens to optimize patient outcomes.

Visit https://www.peervoice.com/CFP860 to view the entire programme with slides. After completing “Alessandro M. Vannucchi, MD, PhD - Not All JAKis Are Equal: What Can Trials and Real-World Evidence Tell Us About Optimal Treatment Approaches in Myelofibrosis?”, participants will be able to: Recall the results of clinical trials and real-world studies evaluating the effects of available Janus kinase (JAK) inhibitors on splenomegaly, symptoms, and cytopenias in patients with myelofibrosis (MF); and Formulate individualised treatment plans for patients with cytopenic MF considering the type and severity of the patient’s specific cytopenia(s).